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Background: The investigational CFTR potentiator ivacaftor (VX-770) increased CFTR channel activity and improved lung function in subjects
with CF who have the G551D CFTR gating mutation. The aim of this in vitro study was to determine whether ivacaftor potentiates mutant CFTR
with gating defects caused by other CFTR gating mutations.
Methods: The effects of ivacaftor on CFTR channel open probability and chloride transport were tested in electrophysiological studies using Fischer rat
thyroid (FRT) cells expressing different CFTR gating mutations.
Results: Ivacaftor potentiated multiple mutant CFTR forms with defects in CFTR channel gating. These included the G551D, G178R, S549N,
S549R, G551S, G970R, G1244E, S1251N, S1255P and G1349D CFTR gating mutations.
Conclusion: These in vitro data suggest that ivacaftor has a similar effect on all CFTR forms with gating defects and support investigation of the
potential clinical beneﬁt of ivacaftor in CF patients who have CFTR gating mutations beyond G551D.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The underlying cause of cystic fibrosis (CF) is the loss of epithe-
lial chloride transport due to mutations in the CF transmembrane
conductance regulator gene (CFTR) that encodes the CFTR pro-
tein (CFTR) [1]. CFTR is an epithelial chloride channel that is
composed of two membrane spanning domains that form the chlo-
ride channel pore, two nucleotide-binding domains (NBD) that
bind and hydrolyze ATP, and a regulatory domain with several
protein kinase A (PKA) phosphorylation sites [1]. The opening
and closing of the CFTR channel pore, or channel gating, is a
tightly regulated process, requiring phosphorylation of the regu-
latory domain by PKA and subsequent ATP binding and hydro-
lysis by the NBDs [2]. Normally, CFTR is present at the
epithelial cell surface where it allows chloride transport across
the epithelial cell membrane to maintain salt, fluid, and pH⁎ Corresponding author at: Vertex Pharmaceuticals Incorporated, 11010 Tor-
reyana Road, San Diego, CA 92121, United States. Tel.: +1 858 404 6642.
E-mail address: fredrick_vangoor@sd.vrtx.com (F. Van Goor).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.12.005balance in multiple organs [3]. In CF, CFTR mutations cause a
loss of chloride transport through CFTR that results in the accu-
mulation of thick, sticky mucus in the bronchi of the lungs, loss
of exocrine pancreatic function, impaired intestinal absorption,
reproductive dysfunction and elevated sweat chloride concentra-
tions [3–4].
There are over 1800 CFTR mutations, resulting in a wide
spectrum in the severity of the loss in chloride transport and
disease phenotype [4]. Evaluation of the molecular defect
caused by some of the more common CFTR mutations has
shown that the loss of chloride transport can be due to a de-
crease in the quantity and/or function of CFTR channels at
the cell surface [4–5]. For example, the most common
CFTR mutation, F508del-CFTR which accounts for two-
thirds of all CFTR alleles in patients with CF [4], impairs
CFTR processing in the endoplasmic reticulum (ER), greatly re-
ducing the quantity of F508del-CFTR protein at the cell surface
[5]. In contrast, approximately 4–5% of patients with CF carry a
missense CFTR mutation that results in CFTR protein which is
present at the cell surface but does not open and close properly
(defective channel gating), resulting in minimal chloride transportby Elsevier B.V. All rights reserved.
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are called CFTR gating mutations (also known as Class III muta-
tions) [5]. The most common CFTR gating mutation in patients
with CF is G551D [6–7]. Other known CFTR gating mutations
include G178R, G551S, G970R, G1244E, S1255P, and
G1349D [9–11].
One potential strategy to treat CF is to increase chloride
transport by restoring or enhancing CFTR function with small
molecule drugs known as CFTR modulators. A CFTR potentia-
tor is a type of CFTR modulator that acts by increasing CFTR
channel gating to enhance chloride transport. For a CFTR poten-
tiator to act, CFTR at the cell surface must first be activated by
PKA-dependent phosphorylation [12]. Experimentally, the effect
of a CFTR potentiator on channel gating can be quantified using
patch-clamp electrophysiology to directly measure the fraction of
time the channel is open, which is called the channel open
probability. Ivacaftor (VX-770), an investigational CFTR po-
tentiator [12], increased the channel open probability of
G551D-CFTR to enhance chloride transport in vitro [12]. In pa-
tients with CFwho have the G551Dmutation, ivacaftor increased
clinical measures of chloride transport through CFTR, and im-
proved clinical measures of lung function [13]. Ivacaftor has
also been shown to potentiate normal CFTR and F508del-
CFTR, suggesting that the compound is not specific for
G551D-CFTR. We therefore hypothesized that ivacaftor might
potentiate multiple mutant CFTR forms with CFTR gating
mutations.
In this set of in vitro studies, the ability of ivacaftor to potentiate
mutant CFTRwas examined in a panel of Fischer rat thyroid (FRT)
cells engineered to express previously reportedCFTR gating muta-
tions orCFTRmutations believed to be located in the ATP binding
sites required for normal channel gating [2]. The results presented
here indicated that ivacaftor potentiated CFTR channel gating
and enhanced chloride transport in all examples of CFTR gating
mutations tested. These in vitro data support the investigation
of the clinical benefit of CFTR potentiators such as ivacaftor,
in patients with CF who have CFTR gating mutations beyond
G551D.
2. Results
2.1. Generation and characterization of cell lines expressing
CFTR gating mutations
To systematically compare the effects of ivacaftor on mutant
CFTR with defective channel gating, a panel of stable cell lines
was generated using FRT cells. Each cell line was engineered to
express a mutant CFTR form with a specific CFTR gating mu-
tation or CFTR mutation believed to be located in the ATP
binding sites required for normal channel gating [2]. These in-
cluded G551D-, G178R-, S549N-, S549R-, G551S-, G970R-,
G1244E-, S1251N-, S1255P-, and G1349D-CFTR [4,7,9–11].
No significant difference (PN0.05; ANOVA followed Tukey's
multiple comparisons test; n=3–6) in the level of CFTR
mRNA was observed between normal CFTR and the individual
mutant CFTR forms expressed in FRT cells (Fig. 1A), suggesting
similar CFTR protein levels.In order to further characterize these cell lines, the delivery
of mutant CFTR protein to the cell surface was indirectly
assessed in immunoblot studies that measure an increase in
the molecular mass of CFTR (from a 135–140 kDa band to a
170–180 kDa band) due to glycosylation (Fig. 1B–D), an indi-
cator of CFTR exit from the endoplasmic reticulum and pas-
sage through the Golgi. After CFTR is processed by the
Golgi, the glycosylated CFTR (mature CFTR) is delivered to
the cell surface [5]. The ratio of mature to total CFTR (ma-
ture+ immature CFTR) was used to estimate the fraction of
CFTR synthesized that was processed normally and delivered
to the cell surface (Fig. 1C). In addition, the steady-state level
of mature mutant CFTR at the cell surface was expressed as a
percentage of that measured in four separate FRT cell lines
expressing normal CFTR (% normal CFTR; Fig. 1D).
F508del-CFTR was used as a reference to calibrate severe de-
fects in CFTR processing and delivery to the cell surface [5].
This analysis showed that, as expected for known CFTR gating
mutations (G551D, G178R, G551S, G970R, G1244E, S1255P,
and G1349D) [5,9–11], the amount of CFTR delivered to the
cell surface was generally similar between CFTR with gating
defects and normal CFTR. In contrast, only a small amount of
F508del-CFTR was delivered to the cell surface (Fig. 1B–D).
Interestingly, there was significantly more G551S-CFTR at
the cell surface than normal CFTR, although the total amount
of G551S-CFTR synthesized and the ratio of mature to total
CFTR were similar to normal CFTR.2.2. Ivacaftor increased the channel gating of mutant CFTR
with defective channel gating
The effect of ivacaftor on CFTR channel gating was moni-
tored by quantifying the channel open probability by patch-
clamp electrophysiology using membrane patches excised
from FRT cells expressing the known CFTR gating mutations,
G551D-, G178R-, G551S-, G970R-, G1244E-, S1255P-, or
G1349D-CFTR. To activate CFTR prior to ivacaftor addition,
PKA (75 nM) and ATP (1 mM) were added to the cytoplasmic
surface (bath solution) of the membrane patch. Under these
conditions, the baseline CFTR channel open probability of
G551D-, G178R-, G551S-, G970R-, G1244E-, S1255P-, and
G1349D-CFTR was ≤5% of normal CFTR (Fig. 2, B;
Table 1). For most mutant CFTR forms, the single channel cur-
rent amplitude, a measure of channel conductance, was similar
to normal CFTR (between 77% and 122% of normal CFTR),
although a small but statistically significant difference in single
channel current amplitude was observed for S1255P-CFTR
(Table 1). Acute (5 min) addition of 10 μM ivacaftor increased
the channel open probability of all CFTR gating mutations
tested, reaching levels equivalent to 30% to 118% of normal
CFTR (Fig. 2B; Table 1). No change in the single channel cur-
rent amplitude was observed following ivacaftor addition
(Table 1). These data indicated that ivacaftor increased the
channel open probability of all mutant CFTR forms with de-
fective channel gating tested to a similar or greater extent
than G551D-CFTR.
239H. Yu et al. / Journal of Cystic Fibrosis 11 (2012) 237–2452.3. Ivacaftor enhanced chloride transport through mutant
CFTR with defective channel gating
The impact of the increase in CFTR channel gating by iva-
caftor on total chloride transport was assessed in Ussing cham-
ber studies using FRT cells expressing the known CFTR gating
mutations, G551D-, G178R-, G551S-, G970R-, G1244E-,
S1255P-, and G1349D-CFTR. To activate CFTR prior to iva-
caftor addition, 10 μM forskolin was added to the bath toN
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The level of chloride transport for each mutant CFTR form
was expressed as a percentage of that measured in four separate
FRT cell lines expressing normal CFTR (% normal-CFTR;
204.5±29.8 μA/cm2). Under these conditions, the baseline
level of chloride transport in FRT cells expressing G551D-,
G178R-, G551S-, G970R-, G1244E-, S1255P-, and G1349D-
CFTR was b10% of normal CFTR (Fig. 3; Table 2), which
was consistent with the low CFTR channel open probability
of these mutant CFTR forms (Table 1). Acute (5-min) ivacaftor
addition caused a N10-fold increase over baseline chloride
transport (Fig. 3; Table 2). Compared to all CFTR gating muta-
tions tested, the ivacaftor response in FRT-cells expressing
F508del-CFTR was minimal (Fig. 3). The EC50 of ivacaftor
for all mutant CFTR forms tested was similar to G551D-
CFTR (range: 161 to 594 nM) (Fig. 3C; Table 2).
2.4. Identification of additional CFTR gating mutations and ef-
fects of ivacaftor
Several of the known CFTR gating mutations cause defects
in one of the two ATP binding pockets formed by the two
NBDs known to regulate CFTR channel gating [2]. The CF-
associated CFTR mutations, S549N, S549R, and S1251N, are
located in the ABC signature sequence (Fig. 4; LSGGQ;
S549N,R in NBD1) and Walker A motif (Fig. 4; S1251N in
NBD2), that form the ATP binding sites [14]. Immunoblot
and Ussing chamber studies indicated that, although the matu-
ration of S549N- and S1251N-CFTR was similar to normal,
the baseline level of chloride transport was b10% of normal
CFTR (Figs. 1 and 3; Table 2). S549R-CFTR showed matura-
tion comparable to 26±2% (n=5) of normal CFTR (Fig. 1D),
which did not account for the b1% of normal CFTR function
(Fig. 3; Table 2). These results indicated that the function of
S549N-, S549R-, and S1251N-CFTR at the cell surface was
minimal. Patch-clamp studies confirmed that the channel open
probability of S549N-, S549R-, and S1251N-CFTR was b5%
of normal CFTR, whereas the single channel current amplitudeFig. 1. CFTR mRNA expression and maturation in FRT cells. A) Mean (±SEM;
n=3–5) levels of CFTR mRNA expression for each CFTR gating mutation
expressed in FRT cells containing the Flp Recombination Target site (pFRT/
lacZeo). For each mutant CFTR protein, the level of CFTR mRNA expression
was normalized to the level of expression for normal CFTR prepared from four
separate FRT cell lines. No significant differences compared to normal CFTR
were observed (PN0.05: ANOVA followed by Tukey's multiple comparison
test). B) Representative immunoblot of the glycosylation pattern of FRT cells
expressing normal and mutant CFTR proteins. The bands associated with im-
mature and mature CFTR are indicated. C) Quantification of the steady-state
CFTR maturation expressed as the mean (±SEM; n=5–9) ratio of mature
CFTR to total CFTR (immature plus mature) in FRT cells individually expres-
sing the CFTR gating mutations indicated. F508del-CFTR was included as a
reference of a severe processing defect that results in minimal CFTR at the
cell surface (n=17). D) Quantification of the level of mature CFTR (±SEM;
n=5–9) expressed as a percentage of normal CFTR. Single asterisk indicates
significant difference (pb0.05; unpaired t-test) compared to normal CFTR
and double asterisk indicates significant difference (pb0.05; unpaired t-test)
compared to normal and F508del-CFTR.
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Fig. 2. Effect of ivacaftor on the channel gating activity of CFTR gating muta-
tions associated with CF. A) Representative patch-clamp tracings (n=3–5 for
each CFTR mutation) in an excised plasma membrane patch from FRT cells
expressing the CFTR gating mutations indicated or normal CFTR. To activate
CFTR, the cytoplasmic surface (bath solution) was exposed to 75 nM PKA
and 1 mM ATP (baseline) prior to application of 10 μM ivacaftor. B) Mean
±SE of the CFTR channel open probability in the absence (baseline; open
bars) or in the presence (filled bars) of 10 μM ivacaftor. Asterisks indicate
significant difference compared to baseline (asterisks indicates pb0.05; paired
t-test; n=3–5).
240 H. Yu et al. / Journal of Cystic Fibrosis 11 (2012) 237–245was 79 to 97% of normal CFTR (Fig. 2; Table 1). Taken to-
gether, these data suggested that defective channel gating was
the predominant defect in S549N-, S549R- and S1251N-CFTR.In FRT cells expressing S549N-, S549R-, and S1251N-
CFTR, acute addition of 10 μM ivacaftor increased the channel
open probability and total chloride transport by N10-fold over
baseline levels (Figs. 2 and 3; Tables 1 and 2). The EC50 for
ivacaftor in FRT cells expressing S549N-, S549R-, and
S1251N-CFTR were similar to G551D-CFTR (Fig. 3C;
Table 2). These results indicated that S549N-, S549R-, and
S1251N-CFTR were potentiated by ivacaftor in vitro.
3. Discussion
CFTR gating mutations result in CFTR which is present at
the cell surface but does not open or close normally, resulting
in a low CFTR channel open probability and the loss of epithe-
lial chloride transport as determined in electrophysiological
studies. In this study we focused on CFTR gating mutations
resulting in minimal channel function and generally associated
with severe CF. The most common CF-causing CFTR gating
mutation is G551D [6] but several other CFTR gating mutations
have been previously reported [9–11]. In a panel of FRT cells
expressing G551D-, G178R-, G551S-, G970R-, G1244E-,
S1255P-, and G1349D-CFTR, we confirmed that all these mu-
tant CFTR forms shared similar in vitro functional characteris-
tics that were consistent with a defect in channel gating. In
addition, we showed that the 3 additional mutations, S549N,
S549R, and S1251N also have characteristics consistent with
gating defects. These characteristics included the delivery of
CFTR to the cell surface, a low (b5%) CFTR channel open
probability, and minimal (b10% normal CFTR) baseline levels
of chloride transport.
Ivacaftor addition caused a N10-fold increase in CFTR-
mediated chloride transport in FRT cells expressing G551D-,
G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-,
S1251N-, S1255P-, and G1349D-CFTR. For all CFTR gating
mutations tested, the level of chloride transport achieved in
the presence of ivacaftor was N10% of normal CFTR, which
exceeds the level of chloride transport associated with lower
sweat chloride levels and a mild CF phenotype [15]. Moreover,
in patients with CF who have the G551D CFTR gating muta-
tion, administration of ivacaftor was associated with improve-
ments in CFTR function, as determined by a reduction in
sweat chloride concentrations, and improvements in lung func-
tion, as determined by an increase in the FEV1 [13]. Taken to-
gether, these in vitro results provide a rationale for testing the
potential benefit of ivacaftor in individuals with CF who have
a CFTR gating mutation other than G551D, including the
G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-,
S1251N-, S1255P, and G1349D CFTR gating mutations.
Evaluation of CF-associated CFTR mutations that were
expected to cause protein alterations in the ATP-binding sites
formed by the NBDs indicated that S549N- and S1251N-
CFTR also shared similar in vitro functional characteristics
with G551D-CFTR and could be classified as CFTR gating
mutations. Unlike S549N-CFTR and S1251N-CFTR, S549R-
CFTR exhibited a partial reduction in the level of CFTR matu-
ration compared to normal CFTR (see also Ref. [16]). The
partial reduction in S549R-CFTR maturation was ~27% of
Table 1
Effect of ivacaftor on the channel gating activity of CFTR with gating mutations.
Single channel current amplitude at 80 mV CFTR channel open probability
Baseline With 10 μM ivacaftor Baseline With 10 μM ivacaftor
Mutation pA % Normal pA % Normal Po % Normal Po % Normal
Normal 0.57±0.03 100 0.63±0.02 111 0.400±0.04 100 0.800±0.04 a 200
G551D 0.46±0.06 81 0.46±0.03 81 0.019±0.01 b 5 0.121±0.035 a 30
G178R 0.59±0.11 103 0.66±0.08 116 0.005±0.001 b 1 0.228±0.022 a 57
S549N 0.55±0.02 97 0.61±0.02 108 0.003±0.010 b 1 0.396±0.119 a 99
S549R 0.45±0.01 b 79 0.55±0.02 a 96 0.004±0.010 b 1 0.143±0.031 a 36
G551S 0.57±0.13 100 0.64±0.02 113 0.010±0.001 b 3 0.337±0.110 a 84
G970R 0.55±0.03 96 0.55±0.03 97 0.001±0.001 b 0 0.245±0.042 a 61
G1244E 0.44±0.11 77 0.54±0.08 94 0.011±0.010 b 3 0.470±0.122 a 118
S1251N 0.54±0.07 95 0.63±0.04 111 0.003±0.010 b 1 0.350±0.03 a 88
S1255P 0.70±0.03 b 122 0.71±0.02 125 0.018±0.016 b 5 0.468±0.168 a 117
G1349D 0.49±0.08 85 0.63±0.06 111 0.019±0.015 b 5 0.315±0.110 a 79
a Significantly different (Pb0.05; paired t-test, n=3–5) compared to baseline levels for each CFTR mutation.
b Significantly different (Pb0.05; unpaired t-test) compared to normal CFTR.
241H. Yu et al. / Journal of Cystic Fibrosis 11 (2012) 237–245normal CFTR and did not appear to be sufficient to account for
the b1% normal CFTR chloride transport in FRT cells expres-
sing this CFTR mutation. Patch-clamp studies showed that the
channel open probability of S549R-CFTR was less than 1%
of normal CFTR. These results indicated that although the pre-
dominant defect caused by the S549R CFTR mutation was de-
fective CFTR channel gating, a mild processing defect was also
observed. The apparent mild processing defect in S549R-CFTR
may account for the lower ivacaftor response in FRT cells
expressing S549R-CFTR compared to the other mutant CFTR
forms with gating defects and normal CFTR maturation.
The low baseline levels of chloride transport in FRT cells
expressingmutant CFTR forms encoded by theCFTR gatingmu-
tations studied here were consistent with the clinical characteris-
tics of patients with CF who carry one of these CFTR gating
mutations. Patients with CF who carry the G551D CFTR gating
mutation have minimal amounts of CFTR function, as deter-
mined by high (~100 mmol/L) sweat chloride concentrations,
and a severe CF phenotype [8,17]. Although there are limited
case studies on patients with CF who have CFTR gating muta-
tions beyond G551D, they also appear to have high sweat chlo-
ride concentrations and severe CF [18–20]. This was consistent
with the low CFTR channel open probability and minimal
(b10% normal CFTR) baseline levels of chloride transport mea-
sured in FRT cells expressing these CFTR gating mutations. A
milder CF clinical phenotype has been associated with the
G551S CFTR gating mutation, as demonstrated by a lower
sweat chloride concentration (75–94 mmol/L) and lower inci-
dence of pancreatic insufficiency compared to patients with CF
who carry the G551D CFTR gating mutation [21]. In the present
study, although the expression and channel open probability of
G551S-CFTR were similar to G551D-CFTR, the baseline chlo-
ride transport was higher (~9% normal CFTR). This may be
due to the increased level of mature G551S-CFTR delivered to
the cell surface compared to normal CFTR, as determined by im-
munoblot studies in FRT cells.
The potency (EC50) of ivacaftor for the CFTR gating muta-
tions tested was similar to G551D in vitro, suggesting that asimilar dose of ivacaftor as that used in clinical trials of patients
with CF who carry the G551D CFTR gating mutation may be
appropriate for most other CFTR gating mutations. Previous
in vitro studies using recombinant cells and primary human air-
way cultures have shown that higher concentrations of ivacaftor
were required to potentiate G551D-CFTR compared to normal-
and F508del-CFTR [12]. The potency of other CFTR potentia-
tors has also been shown to be lower for G551D-CFTR com-
pared to normal or F508del-CFTR [12,22–25]. This suggests
that some CFTR mutations may alter interaction of CFTR po-
tentiators with CFTR to affect channel gating. Further studies
will be needed to identify the ivacaftor binding site on CFTR
to test this hypothesis.
CFTR potentiators from structural classes distinct from iva-
caftor have also been shown to potentiate mutant CFTR with
defective channel gating. These included derivatives of 1,4-
dihydropyridine and phenylglycine which potentiated G551D-,
G970R-, and G1349D-CFTR to a similar extent as ivacaftor
[23,25–26]. In contrast, sulfamoyl-4-oxoquinoline-3-carboxa-
mides were weakly effective on G551D-, G970R-, and
G1349D-CFTR [26] and phloxine B strongly potentiated
G551D-CFTR, but not G1349D-CFTR [22]. Previous studies
have speculated that these differences may be due to distinct
binding sites which may be differentially altered by CFTR mu-
tations or which may modulate CFTR channel gating through
different mechanisms [22–23,26]. These in vitro data have sug-
gested that broad-acting CFTR potentiators, like ivacaftor and
derivatives of 1,4-dihydropyridine and phenylglycine, may
have a wider clinical utility among patients with CF who
have different CFTR gating mutations compared to CFTR po-
tentiators that appear to have an effect on specific CFTR
mutations.
The gating of the CFTR channel pore is a tightly regulated
process, requiring phosphorylation of the regulatory domain
by PKA and subsequent ATP binding and hydrolysis by the
NBDs [2]. Like G551D, the G551S, G1244E, S1255P, and
G1349D CFTR gating mutations, as well as the S549N,
S549R, and S1251N CFTR gating mutations identified in the
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243H. Yu et al. / Journal of Cystic Fibrosis 11 (2012) 237–245present study, cause protein alterations in the ATP binding
pockets formed by the two NBDs required for normal CFTR
channel gating (Fig. 4) [2]. The G178R and G970R CFTR gat-
ing mutations alter the intracellular cytoplasmic loops that are
believed to link the ATP-driven conformational changes in
the NBDs to the opening of the CFTR channel pore formed
by the membrane spanning domains [27]. Given the importance
of these regions in driving CFTR channel opening and closing,
it was not surprising that CFTR mutations associated with these
regions caused severe defects in CFTR channel gating. In vitro,
ivacaftor potentiated mutant CFTR forms associated with alter-
ations in the ATP binding pockets and the cytoplasmic loops
linking the CFTR channel pore to the movement of the
NBDs, suggesting that ivacaftor may bypass or augment
ATP-dependent channel gating of mutant CFTR to potentiate
the function of PKA-activated CFTR. Additional studies are
needed to determine the ATP dependence and molecular mech-
anism of CFTR potentiation by ivacaftor.
In previous in vitro studies ivacaftor potentiated chloride
transport by normal and F508del-CFTR [12]. Along with the
data presented here on multiple mutant CFTR forms with de-
fective channel gating, ivacaftor appeared to be a broad-acting
CFTR potentiator. This suggests that ivacaftor may act on
other mutant CFTR forms that are delivered to the cell surface
in sufficient amounts. For example, R117H-CFTR is delivered
to the cell surface in normal amounts, but exhibits a ~20% re-
duction in CFTR channel conductance and a ~75% reduction
in the channel open probability, resulting in residual CFTR
function both in vitro and clinically [28]. Other CFTR gene mu-
tations associated with residual CFTR function include A445E,
R347H, D1152H, and certain splice mutations (3849
+10kbC→T) [4,29–30]. Further in vitro studies and clinical
measurements are needed to evaluate the ivacaftor response
and potential clinical benefit for CFTR mutations beyond
CFTR gating mutations.
In conclusion, ivacaftor increased the channel gating activity
of all mutant CFTR forms associated with CFTR gating muta-
tions tested in this study, resulting in enhanced chloride trans-
port. This suggested that ivacaftor is not a mutation-specific
CFTR potentiator, as it overcomes the underlying molecular
defect caused by G551D and a number of other CFTR gating
mutations. As a group these CFTR gating mutations shared
the following characteristics; 1) defective CFTR channel gating
as the predominant molecular defect, 2) residual or normal
amounts of CFTR present at the cell surface, 3) minimal base-
line chloride transport in vitro (b10% normal), and 4) a pro-
nounced (N10-fold) increase over baseline chloride transportFig. 3. Effect of ivacaftor on chloride transport in FRT cells expressing CFTR gatin
stimulated chloride transport in the absence (baseline; dotted line) and presence (so
gating mutation indicated. F508del-CFTR was included as a reference. Forskolin (1
cellular concentrations of cAMP. B) The mean (±SEM; n=4–6) CFTR-mediated
open bars) or in the presence (filled bars) of 10 μM ivacaftor in FRT cells expressing
CFTR function, the forskolin-stimulated chloride transport in FRT cells expressing m
separate FRT cell lines expressing normal CFTR (204.5±29.8 μA/cm2) and expres
compared to baseline (pb0.05; paired t-test; n=4–6). C) Concentration response rel
cated (mean±SEM; n=4–6).in response to ivacaftor. The in vitro data presented here sug-
gest that ivacaftor has a similar effect on all CFTR forms with
gating defects and support the investigation of ivacaftor in pa-
tients with CF who have CFTR gating mutations beyond
G551D, including G178R, S549N, S549R, G551S, G970R,
G1244E, S1251N, S1255P, and G1349D.4. Methods
4.1. Cell line generation
A panel of FRT cell lines expressing differentCFTRmutations
was generated using a host cell line with a single integration site as
described in the supplementary material.4.2. RNA analysis
Total RNA was isolated and real-time PCR assays were per-
formed as described in the Supplementary material.4.3. Electrophysiology
Ussing chamber techniques using FRT cells were used to re-
cord the IT due to CFTR-mediated chloride transport. The
single-channel activity of CFTR was measured using excised
inside-out membrane patch recordings (see Supplementary
material).4.4. CFTR immunoblot analysis
Immunoblot techniques using the monoclonal CFTR anti-
body 769 (J. Riordan, University of North Carolina) were
used to measure CFTR maturation in FRT, HEK-293, or HBE
cells expressing wild-type- or F508del-CFTR (see Supplemen-
tary material).Acknowledgments
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manuscript.g mutations associated with CF. A) Representative recordings of the forskolin-
lid line) of 10 μM ivacaftor in FRT cell expressing normal CFTR or the CFTR
0 μM; arrows) was added to the bath to activate CFTR by increasing the intra-
chloride transport (left y-axis) with 10 μM forskolin in the absence (baseline;
normal CFTR and the mutant CFTR proteins indicated. To compare to normal
utant CFTR was normalized to the forskolin-stimulated chloride transport in 4
sed as % normal CFTR (right y-axis). Asterisks indicate significant difference
ationship for ivacaftor in FRT cells expressing the CFTR gating mutations indi-
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Fig. 4. Location of the amino acid alterations associated withCFTR gatingmutations
tested in this study. CFTR is composed of twomembrane spanning domains (MSDs)
that form an anion-selective pore, two NBDs that contain the LSGGQ andWalker A
and B (bold solid lines) motifs that form the twoATP binding pockets (sites 1 and 2),
and a regulatory domain (R) that contain the PKA phosphorylation sites. Intracellular
cytoplasmic loops connecting the membranes spanning domains are believed to act
as molecular linkers to transfer the ATP-dependent conformational changes in the
NBDs to the MSD, thereby opening the CFTR channel pore formed by the mem-
branes spanning domains. The CFTR gating mutations tested here are believed to
cause protein alterations in the ATP binding sites and cytoplasm loops.
Table 2
Baseline chloride transport and pharmacological effect of ivacaftor in cultured FRT cells expressing CFTR gating mutations.
Chloride transport (μA/cm2) Chloride transport (% normal)
Mutation Baseline With ivacaftor Baseline With ivacaftor Fold change a EC50
b
G551D 1.5±0.7 113.2±13.0 c 1.0±0.5 55.3±6.3 c 55 312±73
G178R 6.0±1.1 178.4±16.8 c 2.9±0.5 87.2±8.2 c 30 178±43
S549N 3.3±0.8 195.8±13.4 c 1.6±0.4 95.7±6.5 c 59 124±43
S549R 0.1±0.1 43.0±12.5 c 0.0±0.0 21.0±6.1 c N20 182±23
G551S 19.8±1.5 322.3±18.8 c 9.7±0.7 157.6±9.2 c 16 161±51
G970R 3.3±1.2 99.8±20.0 c 1.6±0.6 48.8±9.8 c 31 514±91
G1244E 0.6±0.2 79.6±4.6 c 0.3±0.1 38.9±2.2 c 130 594±105
S1251N 8.1±1.5 200.9±17.6 c 3.9±0.7 98.2±8.6 c 25 245±69
S1255P 1.6±0.5 119.6±22.8 c 0.8±0.2 58.5±11.1 c 73 192±45
G1349D 3.6±1.0 162.1±8.4 c 1.7±0.5 79.3±4.1 c 47 315±13
a The fold change in chloride transport was determined by dividing the level of chloride transport (% normal) in the presence of ivacaftor by the baseline chloride transport.
b No significant differences (PN0.05; unpaired t-test, n=4–6) compared to G551D-CFTR was observed for any of the mutant CFTR forms tested.
c Significant difference compared to baseline (pb0.05; paired t-test; n=4–6).
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Supplementary data to this article can be found online at
doi:10.1016/j.jcf.2011.12.005.References
[1] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z,
et al. Identification of the cystic fibrosis gene: cloning and characterization
of complementary DNA. Science 1989 Sep 8;245(4922):1066–73.
[2] Hwang TC, Sheppard DN. Gating of the CFTR Cl- channel by ATP-
driven nucleotide-binding domain dimerisation. J Physiol 2009 May
15;587(Pt 10):2151–61.[3] Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface
dehydration. Trends Mol Med 2007 Jun;13(6):231–40.
[4] Castellani C, Cuppens H, Macek Jr M, Cassiman JJ, Kerem E, Durie P,
et al. Consensus on the use and interpretation of cystic fibrosis mutation
analysis in clinical practice. J Cyst Fibros 2008 May;7(3):179–96.
[5] Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel
dysfunction in cystic fibrosis. Cell 1993 Jul 2;73(7):1251–4.
[6] Bobadilla JL, Macek Jr M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide
analysis of CFTR mutations—correlation with incidence data and application
to screening. Hum Mutat 2002 Jun;19(6):575–606.
[7] Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective func-
tion of the cystic fibrosis-causing missense mutation G551D is recovered by
genistein. Am J Physiol 1999 Oct;277(4 Pt 1):C833–9.
[8] McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype
on phenotype and mortality in cystic fibrosis: a retrospective cohort
study. Lancet 2003 May 17;361(9370):1671–6.
[9] Anderson MP, Welsh MJ. Regulation by ATP and ADP of CFTR chloride
channels that contain mutant nucleotide-binding domains. Science 1992
Sep 18;257(5077):1701–4.
[10] Seibert FS, Jia Y, Mathews CJ, Hanrahan JW, Riordan JR, Loo TW, et al.
Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis
transmembrane conductance regulator impede processing or opening of the
channel. Biochemistry 1997 Sep 30;36(39):11966–74.
[11] Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Riordan JR, Clarke DM. Cy-
toplasmic loop three of cystic fibrosis transmembrane conductance regulator
contributes to regulation of chloride channel activity. J Biol Chem 1996
Nov 1;271(44):27493–9.
[12] Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al.
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator,
VX-770. Proc Natl Acad Sci U S A 2009 Nov 3;106(44):18825–30.
[13] Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al.
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR
Mutation. N Engl J Med 2010 Nov 18;363(21):1991–2003.
[14] Frelet A, KleinM. Insight in eukaryotic ABC transporter function bymutation
analysis. FEBS Lett 2006 Feb 13;580(4):1064–84.
[15] Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit
Care Med 1996 Nov;154(5):1229–56.
[16] Van Oene M, Lukacs GL, Rommens JM. Cystic fibrosis mutations lead to
carboxyl-terminal fragments that highlight an early biogenesis step of the
cystic fibrosis transmembrane conductance regulator. J Biol Chem 2000
Jun 30;275(26):19577–84.
[17] Comer DM, Ennis M, McDowell C, Beattie D, Rendall J, Hall V, et al.
Clinical phenotype of cystic fibrosis patients with the G551D mutation.
QJM 2009 Nov;102(11):793–8.
[18] Lissens W, Bonduelle M, Malfroot A, Dab I, Liebaers I. A serine to proline
substitution (S1255P) in the second nucleotide binding fold of the cystic fibro-
sis gene. Hum Mol Genet 1992 Sep;1(6):441–2.
245H. Yu et al. / Journal of Cystic Fibrosis 11 (2012) 237–245[19] Zielenski J, Bozon D, Kerem B, Markiewicz D, Durie P, Rommens JM,
et al. Identification of mutations in exons 1 through 8 of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. Genomics 1991
May;10(1):229–35.
[20] Storm K, Moens E, Vits L, De Vlieger H, Delaere G, D'Hollander M,
et al. High incidence of the CFTR mutations 3272–26A–NG and L927P
in Belgian cystic fibrosis patients, and identification of three new CFTR
mutations (186–2A–NG, E588V, and 1671insTATCA). J Cyst Fibros
2007 Nov 30;6(6):371–5.
[21] Orozco L, Lezana JL, Villarreal MT, Chavez M, Carnevale A. Mild cystic
fibrosis disease in three Mexican delta-F508/G551S compound heterozy-
gous siblings. Clin Genet 1995 Feb;47(2):96–8.
[22] Cai Z, Taddei A, Sheppard DN. Differential sensitivity of the cystic fibrosis
(CF)-associatedmutantsG551D andG1349D to potentiators of the cystic fibro-
sis transmembrane conductance regulator (CFTR) Cl- channel. J Biol Chem
2006 Jan 27;281(4):1970–7.
[23] Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the
cystic fibrosis transmembrane conductance regulator in the nucleotide
binding domains. Cell Mol Life Sci 2005 Feb;62(4):446–60.
[24] Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, et al.
Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis
transmembrane conductance regulator channel gating defect caused by
cystic fibrosis mutations. Mol Pharmacol 2005 Dec;68(6):1736–46.[25] Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen
YF, et al. Phenylglycine and sulfonamide correctors of defective delta
F508 and G551D cystic fibrosis transmembrane conductance regulator
chloride-channel gating. Mol Pharmacol 2005 May;67(5):1797–807.
[26] Caputo A, Hinzpeter A, Caci E, Pedemonte N, Arous N, Di Duca M, et al.
Mutation-specific potency and efficacy of cystic fibrosis transmembrane
conductance regulator chloride channel potentiators. J Pharmacol Exp
Ther 2009 Sep;330(3):783–91.
[27] He L, Aleksandrov AA, Serohijos AW, Hegedus T, Aleksandrov LA, Cui L,
et al. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis
transmembrane conductance regulator (CFTR)mediate regulation of channel
gating. J Biol Chem 2008 Sep 26;283(39):26383–90.
[28] Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh
MJ. Mutations in CFTR associated with mild-disease-form Cl- channels
with altered pore properties. Nature 1993 Mar 11;362(6416):160–4.
[29] Fulmer SB, Schwiebert EM, Morales MM, Guggino WB, Cutting GR. Two
cystic fibrosis transmembrane conductance regulator mutations have differ-
ent effects on both pulmonary phenotype and regulation of outwardly recti-
fied chloride currents. Proc Natl Acad Sci U SA 1995 Jul 18;92(15):6832–6.
[30] Sheppard DN, Ostedgaard LS,WinterMC,WelshMJ.Mechanism of dysfunc-
tion of two nucleotide binding domain mutations in cystic fibrosis transmem-
brane conductance regulator that are associated with pancreatic sufficiency.
EMBO J 1995 Mar 1;14(5):876–83.
